Seagen Inc has been given FDA Accelerated Approval for its colorectal drug TUKYSA (tucatinib) after reviewing positive data from the MOUNTAINEER phase 2 trial. TUKYSA, in combination with trastuzumab, is used for people who have previously been treated for RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer which has progressed following treatments with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy.
FDA grants Accelerated Approval for Seagen’s colorectal cancer treatment
